Cambridge Financial Group (Arizona)’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Sell
886
-30
-3% -$30.7K 0.33% 58
2026
Q1
$843K Buy
916
+48
+6% +$48.7K 0.29% 64
2025
Q4
$670K Sell
868
-23
-3% -$22K 0.23% 78
2025
Q3
$680K Buy
891
+15
+2% +$11.2K 0.22% 84
2025
Q2
$683K Sell
876
-263
-23% -$204K 0.26% 66
2025
Q1
$940K Hold
1,139
0.4% 53
2024
Q4
$879K Sell
1,139
-30
-3% -$24.8K 0.38% 52
2024
Q3
$1.04M Buy
1,169
+110
+10% +$98.9K 0.43% 52
2024
Q2
$959K Buy
1,059
+8
+0.8% +$6.4K 0.44% 52
2024
Q1
$818K Sell
1,051
-76
-7% -$54.1K 0.39% 56
2023
Q4
$657K Buy
+1,127
New +$658K 0.34% 57

Other funds holding LLY

Cambridge Financial Group (Arizona)'s LLY Position: Q2 2026 in Review

Cambridge Financial Group (Arizona) reduced its Eli Lilly (LLY) stake by 3.3% in Q2 2026, selling an estimated $30.7K and leaving 886 shares worth $1.06M. The position accounts for 0.33% of the portfolio, ranked #58.

Cambridge Financial Group (Arizona) first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cambridge Financial Group (Arizona) held 886 shares of Eli Lilly worth $1.06M as of Q2 2026.
  • Cambridge Financial Group (Arizona) sold 30 Eli Lilly shares in Q2 2026, an estimated $30.7K.
  • Eli Lilly made up 0.33% of Cambridge Financial Group (Arizona)'s portfolio in Q2 2026, its #58 holding.
  • Cambridge Financial Group (Arizona) first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cambridge Financial Group (Arizona)'s 13F filing for Q2 2026, filed 14 Jul 2026.